Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report

[1]  Liqin Zhu,et al.  Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. , 2017, International journal of antimicrobial agents.

[2]  D. Denning,et al.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. Zhai,et al.  Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis , 2016, The Journal of antimicrobial chemotherapy.

[4]  E. R. van den Heuvel,et al.  Inflammation Is Associated with Voriconazole Trough Concentrations , 2014, Antimicrobial Agents and Chemotherapy.

[5]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  T. Fujita,et al.  Early Enteral Nutrition Reduces the Rate of Life-Threatening Complications after Thoracic Esophagectomy in Patients with Esophageal Cancer , 2012, European Surgical Research.

[7]  Devona Williams.  The effect of enteral nutrition supplements on serum voriconazole levels , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[8]  J. Fish,et al.  Recommendations for the use of medications with continuous enteral nutrition. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Piens,et al.  Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  N. Wood,et al.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.

[12]  F. Dromer,et al.  Serum Voriconazole Levels following Administration via Percutaneous Jejunostomy Tube , 2003, Antimicrobial Agents and Chemotherapy.

[13]  M. Rinaldi,et al.  Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.

[14]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[15]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[16]  H. Itoh,et al.  Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension via Enteral Feeding Tube in Intensive Care Unit Patients. , 2021, Biological & pharmaceutical bulletin.

[17]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[18]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..